This handout is for acute decompensated heart failure. Your care team identified this based on: acute dyspnea / orthopnea / pnd (acc/aha 2022 §10.1).
Other reasons your team may use this plan: pulmonary edema on exam / lung us b-lines (esc 2021 §11); nt-probnp elevated for age (pride, januzzi nejm 2006); sbp <90 or hypoperfusion (scai 2022 cs staging).
Take these medications exactly as prescribed. Do not stop or change a dose without talking to your provider.
| Medication | Starting dose | How | When | What it does |
|---|---|---|---|---|
| furosemide | IV bolus 2–2.5× total daily home dose (e.g. 80–160 mg IV) | IV | q12h or continuous infusion 5–20 mg/h | DOSE (Felker NEJM 2011) — high-dose intermittent IV loop is reasonable; check urine output at 2 h |
| torsemide | 20–40 mg IV | IV/PO | BID | TRANSFORM-HF (Mentz JAMA 2023) — equivalent outcomes; better PO bioavailability |
| bumetanide | 1–2 mg IV | IV/PO | q4–8h | Alternative loop diuretic (ACC/AHA 2022 §10.3) |
| acetazolamide | 500 mg IV/PO | IV/PO | once daily × 3 | ADVOR (Mullens NEJM 2022) — improves decongestion at 3 d when added to loop |
| metolazone | 2.5–10 mg | PO | once daily | CLOROTIC (Trullàs Eur J Heart Fail 2023) — sequential nephron blockade for refractory congestion |
| hydrochlorothiazide | 25 mg | IV/PO | once daily | Alternative thiazide for sequential blockade (ESC 2021 §11.3) |
| nitroglycerin | 5–10 µg/min IV | IV | continuous; titrate by 5 µg/min q5min | Afterload reduction — fastest onset in pulmonary edema (ESC 2021 Class IIa) |
Plan: ADHF — wet/cold profile based decongestion + perfusion + GDMT initiation (Nohria-Stevenson 2002; ACC/AHA 2022)
Contact your care team if any of the following happen:
Call 911 or go to the nearest emergency room right away if you have:
Guideline: 2022 AHA/ACC/HFSA HF Guideline + 2023 AHA/ACC/HFSA Focused Update + 2021/2023 ESC HF